NextCell Pharma AB (DE:65G)
FRANKFURT:65G
Want to see DE:65G full AI Analyst Report?
65G Stock Chart & Stats
€0.05
>-€0.01(-2.19%)
At close: 4:00 PM EST
€0.05
>-€0.01(-2.19%)
Day’s Range― - ―
52-Week Range€0.05 - €0.17
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€11.77M
Enterprise Value€101.85M
Total Cash (Recent Filing)€26.03M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding111,392,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.36
Price to Sales (P/S)8.24
P/FCF Ratio-2.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€1.31M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially reduces refinancing and interest-rate risk for a cash-burning biotech. This structural strength preserves flexibility to raise equity or partner non-dilutive financing, helping sustain R&D programs and clinical timelines over the next 2–6 months without imminent debt pressure.
Focused Cell-therapy PlatformA concentrated platform around MSC-based cell therapies provides durable strategic clarity and potential for deep technical expertise and IP build-up. This specialization aligns the company with expanding regenerative-medicine demand and supports sustained clinical development and partner interest over the medium term.
Lean Operating StructureA very small headcount implies a lean cost base that can extend runway and focus spend on core R&D activities. Structurally, low fixed overhead supports flexibility in resource allocation, enabling the company to prioritize pivotal trials or partnerships without large incremental SG&A burdens.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows are a structural vulnerability: the business requires continual external financing to fund operations and trials. Over several months this elevates dilution and financing execution risk, potentially disrupting clinical programs or slowing development timelines if capital access tightens.
Negative Gross Profit And MarginsNegative gross profit means current costs exceed revenues, indicating the core model isn't yet scaling sustainably. Deep operating and net losses create a structural need to either materially grow revenue or cut costs; absent that, profitability remains distant and investor dependence on recurring funding persists.
Eroding Equity BaseA sharply reduced equity cushion lowers the company's financial buffer, increasing vulnerability to shocks and making future capital raises more dilutive or costly. Structurally this heightens funding risk for ongoing trials and may constrain strategic optionality over the medium term unless operating losses reverse.
65G FAQ
What was NextCell Pharma AB’s price range in the past 12 months?
NextCell Pharma AB lowest stock price was €0.05 and its highest was €0.17 in the past 12 months.
What is NextCell Pharma AB’s market cap?
NextCell Pharma AB’s market cap is €11.77M.
When is NextCell Pharma AB’s upcoming earnings report date?
NextCell Pharma AB’s upcoming earnings report date is May 28, 2026 which is in 27 days.
How were NextCell Pharma AB’s earnings last quarter?
NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.002.
Is NextCell Pharma AB overvalued?
According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued.
Does NextCell Pharma AB pay dividends?
NextCell Pharma AB does not currently pay dividends.
What is NextCell Pharma AB’s EPS estimate?
NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NextCell Pharma AB have?
NextCell Pharma AB has 111,392,960 shares outstanding.
What happened to NextCell Pharma AB’s price movement after its last earnings report?
NextCell Pharma AB reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NextCell Pharma AB?
Currently, no hedge funds are holding shares in DE:65G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Nanologica AB
―
Biovica International AB Class B
―
Modus Therapeutics Holding AB
―